Published in Clin J Am Soc Nephrol on May 30, 2007
Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov (2012) 2.33
Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol (2009) 1.03
Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis (2014) 1.01
Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes (2014) 0.98
Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy. Diabetes (2013) 0.97
Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens (2009) 0.92
Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv Chronic Kidney Dis (2011) 0.84
Present and future in the treatment of diabetic kidney disease. J Diabetes Res (2015) 0.84
Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. Diabetes Spectr (2015) 0.83
Therapeutic Modalities in Diabetic Nephropathy: Future Approaches. Open J Nephrol (2012) 0.81
Protein kinase C-beta inhibition: a promise not yet fulfilled. Clin J Am Soc Nephrol (2007) 0.79
Tandem inhibition of PKC in Diαβetic nephropathy: it takes two to tango? Diabetes (2013) 0.78
Pectinase-Processed Ginseng Radix (GINST) Ameliorates Hyperglycemia and Hyperlipidemia in High Fat Diet-Fed ICR Mice. Biomol Ther (Seoul) (2012) 0.77
PKCδ promotes high glucose induced renal tubular oxidative damage via regulating activation and translocation of p66Shc. Oxid Med Cell Longev (2014) 0.76
Dual protein kinase C alpha and beta inhibitors and diabetic kidney disease: a revisited therapeutic target for future clinical trials. J Diabetes Investig (2013) 0.75
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr Crit Care Med (2006) 2.19
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2007) 2.14
Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med (2010) 2.11
Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care (2013) 2.03
Anxiety and poor glycemic control: a meta-analytic review of the literature. Int J Psychiatry Med (2002) 2.02
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care (2003) 1.85
Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther (2003) 1.74
The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol (2005) 1.66
Body weight changes with beta-blocker use: results from GEMINI. Am J Med (2007) 1.60
Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis (2002) 1.58
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension (2005) 1.54
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) (2012) 1.53
Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry (2006) 1.45
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol (2007) 1.45
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care (2005) 1.36
Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol (2006) 1.35
A multilevel ecological approach to promoting walking in rural communities. Prev Med (2005) 1.30
Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis (2012) 1.28
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J (2005) 1.25
Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control. J Am Coll Cardiol (2005) 1.25
Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One (2013) 1.24
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc (2003) 1.22
Depression and coronary heart disease in women with diabetes. Psychosom Med (2003) 1.15
Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans. Am J Physiol Endocrinol Metab (2002) 1.11
Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans. Obesity (Silver Spring) (2011) 1.02
An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford) (2013) 0.99
Epidemiology of obesity and chronic kidney disease. Adv Chronic Kidney Dis (2006) 0.98
Efficacy of sertraline in prevention of depression recurrence in older versus younger adults with diabetes. Diabetes Care (2007) 0.98
Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry. Diabetes Care (2013) 0.97
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol (2002) 0.96
Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. J Am Diet Assoc (2003) 0.93
Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract (2013) 0.91
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care (2007) 0.91
A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis (2003) 0.91
How the diabetic eye loses vision. Endocrine (2007) 0.90
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Endocr Pract (2017) 0.90
Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med (2012) 0.88
The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J Manag Care Pharm (2007) 0.87
Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care (2005) 0.86
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract (2015) 0.85
How to make exercise counseling more effective: lessons from rural America. J Fam Pract (2008) 0.85
Reduction in insulin sensitivity following administration of the clinically used low-dose pressor, norepinephrine. Diabetes Metab Res Rev (2011) 0.85
Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis (2013) 0.85
High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. Am J Med Sci (2010) 0.85
Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab (2002) 0.84
Weight-bearing versus nonweight-bearing exercise for persons with diabetes and peripheral neuropathy: a randomized controlled trial. Arch Phys Med Rehabil (2012) 0.84
Impact of sex on the heart's metabolic and functional responses to diabetic therapies. Am J Physiol Heart Circ Physiol (2013) 0.84
Treatment of blocked elbow flexion in congenital radioulnar synostosis with radial head excision: a case series. J Pediatr Orthop (2013) 0.84
Prediction and prevention of treatment-related inpatient hypoglycemia. J Diabetes Sci Technol (2012) 0.83
Alterations in left ventricular structure and function in type-1 diabetics: a focus on left atrial contribution to function. J Am Soc Echocardiogr (2006) 0.81
Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens (2007) 0.81
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2015 EXECUTIVE SUMMARY. Endocr Pract (2015) 0.80
Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clin J Am Soc Nephrol (2013) 0.80
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev (2012) 0.80
Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine. Ann Pharmacother (2014) 0.80
Continued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trial. Diabetes Technol Ther (2007) 0.80
Prevention of inpatient hypoglycemia with a real-time informatics alert. J Hosp Med (2014) 0.80
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich) (2007) 0.79
Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism (2002) 0.79
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr (2008) 0.78
Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis. J Crit Care (2011) 0.78
Inpatient glycemic control on the vascular surgery service. Endocr Pract (2008) 0.77
Psychosocial factors in patients with chronic kidney disease. Adv Chronic Kidney Dis (2007) 0.77
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. Diabetes Care (2007) 0.76
MAXIMIZING PATIENT SAFETY WITH NEWLY APPROVED THERAPIES: FOCUS ON SGLT2 INHIBITORS. Endocr Pract (2015) 0.75
Approach to obesity in patients with pelvic floor dysfunction. J Reprod Med (2009) 0.75
Severe ovarian hyperstimulation syndrome in patients with autoimmune disorders: a report of two cases. J Reprod Med (2015) 0.75
PITUITARY DYSFUNCTION IN DEVELOPMENTAL DELAY: MEDICAL AND ETHICAL CONCERNS. Endocr Pract (2015) 0.75
The decrease in microalbuminuria with carvedilol therapy is not enhanced by concurrent use of a statin. Endocr Pract (2008) 0.75
Hyperandrogenism and intersex controversies in women's olympics. J Clin Endocrinol Metab (2012) 0.75
HIGH-RISK GASTRIC PATHOLOGY AND PREVALENT AUTOIMMUNE DISEASES IN PATIENTS WITH PERNICIOUS ANEMIA. Endocr Pract (2017) 0.75